It's good to see you again, myeloma world.

We got tied up the past couple days with, among other things, coverage of the Empliciti approval in Europe. But we're glad to be back and we have two new research studies that we'd like to discuss with you.

First, we take a look at an Israeli study that does a deep dive into the t(11;14) chro­mosomal abnormality in newly diagnosed multiple myeloma patients. The focus of this particular deep dive is the impact other chro­mosomal abnormalities have on the prognosis of newly …

Good morning, myeloma world.

It's been a very chilly morning here at Myeloma Morning Headquarters. After teasing us with summerlike temperatures the past few weeks, Mother Nature has decided she's not done with the part of the thermometer below freezing.

We'll be focusing on two new research studies in today's report.

The first study looks at outcomes of allogeneic (donor) stem cell trans­plan­ta­tion for multiple myeloma. Using outcomes from a single U.S. treatment center, the study authors find that whether or not an allo­geneic trans­plant patient had high-risk disease at diagnosis did …

Good morning, myeloma world.

After a particularly busy inaugural edition of Myeloma Morning, today's edition doesn't have quite as much ground to cover. We'll be focusing most of today's discussion on just four new research studies that have been published.

That being said, the first of those studies is going to require more than the usual amount of attention.

That's because the study is a new International Myeloma Working Group (IMWG) consensus state­ment concerning high-risk cytogenetics – a subject of significant interest to almost everyone in myeloma world (

A poster session yesterday at the 2015 American Society of Clinical Oncology (ASCO) annual meeting was the venue for the first substantial dose of multiple myeloma-related presentations at the conference.

During the session, research results were made available for review by meeting attendees in the form of posters, each of which summarized the results of a single study. As is typically the case during such sessions, each poster was about two feet high by three or four feet in length. All posters were displayed throughout a large conference hall.

Most of the …

The 51st annual meeting of the American Society of Clinical Oncology (ASCO) started earlier to­day, May 29, and will go through June 2 in Chicago.

Approximately 30,000 physicians and re­searchers from all over the world are ex­pec­ted to attend the five-day meeting to discuss cur­rent re­search in cancer treat­ment and care.

During the meeting, there will be pre­sen­ta­tions about all types of cancer, in­clud­ing many pre­sen­ta­tions focused spe­cif­i­cally on mul­ti­ple myeloma. In fact, more than 90 myeloma-related stud­ies are scheduled to be pre­sented, in one form or another, in con­nec­tion with the …

The results of a recently published study show that, among newly diag­nosed myeloma patients, African-Americans are less likely than white Americans to have the four most common myeloma-related chro­mo­somal ab­nor­mal­ities.

The authors of the study investigated how often the chro­mo­somal ab­nor­mal­ities t(11;14), t(4;14), del(13q), and del(17p) were present in two dif­fer­ent groups of newly diagnosed myeloma patients. One group con­sisted of African-Americans, the other of white Americans.

Each of the four ab­nor­mal­ities occurred less frequently in the African-American patients.

In addition, almost two-thirds of the African-American patients (63 per­cent) did not have …

The 2014 International Myeloma Working Group (IMWG) Annual Summit took place in Milan, Italy on June 9 and 10.

The summit is a special meeting organized by the International Myeloma Foun­da­tion in which leading myeloma researchers get to brainstorm col­lectively about the most pressing issues in the field, find ways to col­lab­o­rate, and plan future laboratory and clinical studies.

The IMWG summit is hailed by most attendees as the most important meeting for myeloma researchers worldwide. It is a unique opportunity for investigators in the field to engage in lively debate but, …